Overview
Jazz Pharmaceuticals plc is a biopharmaceutical company headquartered in Dublin, Ireland. The company specializes in developing and commercializing pharmaceutical products aimed at addressing unmet medical needs, particularly in the fields of neuroscience and oncology. Key areas of focus include sleep disorders and hematologic malignancies. A notable project is the development and commercialization of Xywav, an oxybate medication approved for conditions such as narcolepsy. Jazz Pharmaceuticals pursues both organic growth through drug development and strategic acquisitions to enhance its product portfolio and expand its market reach globally. This integrated approach helps the company maintain a leading position in its specialized therapeutic areas.
Basic Stats
The share price of Jazz Pharmaceuticals plc - Depositary Receipt (Common Stock) as of September 23, 2024 is R$40.48 / share. The market cap (or net worth) of Jazz Pharmaceuticals plc - Depositary Receipt (Common Stock) as of September 5, 2025 is R$2,477.13 MM.
The Factor Analysis chart (below right) shows a view of Jazz Pharmaceuticals plc - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 2,477.13 MM |
| EV | |
| Shares Out. | 61.19 MM |
| Earnings Date | |
| EPS (TTM) | -6.62 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.04 |
| Beta | -1.16 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.04 |
| ROE | -0.11 |
| ROIC | -0.04 |
| CROIC | -0.02 |
| OCROIC | 0.14 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 79.22 /100 |
| Profitability | 42.39 /100 |
| Quality Score | 62.25 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 97.97 /100 |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Jazz Pharmaceuticals plc - Depositary Receipt (Common Stock) is R$75.92. The forecasts range from a low of R$59.31 to a high of R$94.54. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Jazz Pharmaceuticals plc - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-07-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-07-02 | UBS | Neutral | Neutral | Maintains |
| 2024-06-20 | Needham | Buy | Buy | Maintains |
| 2024-06-05 | Goldman Sachs | Buy | Initiate | |
| 2024-05-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-03 | Barclays | Overweight | Overweight | Maintains |
| 2024-05-02 | Needham | Buy | Buy | Reiterate |
| 2024-04-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-20 | Truist Securities | Buy | Buy | Reiterate |
| 2024-03-20 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-03-20 | Needham | Buy | Buy | Reiterate |
| 2024-03-15 | Stifel | Buy | Buy | Maintains |
| 2024-03-14 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-03-01 | UBS | Neutral | Neutral | Maintains |
| 2024-03-01 | Barclays | Overweight | Overweight | Maintains |
| 2024-02-29 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-29 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-02-29 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-02-29 | Needham | Buy | Buy | Maintains |
| 2024-01-29 | Barclays | Overweight | Overweight | Maintains |
| 2024-01-03 | Baird | Outperform | Initiate | |
| 2023-12-04 | Truist Securities | Buy | Buy | Reiterate |
| 2023-11-29 | Needham | Buy | Buy | Reiterate |
| 2023-11-27 | UBS | Buy | Neutral | Downgrade |
| 2023-11-09 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-11-09 | Needham | Buy | Buy | Maintains |
| 2023-09-29 | Raymond James | Market Perform | Initiate | |
| 2023-08-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-14 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-08-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-10 | B of A Securities | Buy | Buy | Maintains |
| 2023-08-10 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-08-10 | Needham | Buy | Buy | Reiterate |
| 2023-08-07 | Needham | Buy | Buy | Reiterate |
| 2023-07-11 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2023-06-05 | Needham | Buy | Buy | Reiterate |
| 2023-05-30 | Needham | Buy | Buy | Reiterate |
| 2023-05-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-05-15 | Needham | Buy | Buy | Reiterate |
| 2020-07-28 | Wolfe Research | Peer Perform | Outperform | Upgrade |
| 2023-05-11 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-05-11 | Needham | Buy | Buy | Maintains |
| 2023-03-06 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-03-03 | Goldman Sachs | Buy | Maintains | |
| 2023-03-02 | Needham | Buy | Maintains | |
| 2022-12-09 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2022-11-10 | Goldman Sachs | Neutral | Maintains | |
| 2022-11-10 | RBC Capital | Outperform | Maintains | |
| 2022-11-10 | Needham | Buy | Maintains | |
| 2022-09-29 | Goldman Sachs | Neutral | Maintains | |
| 2022-09-21 | Goldman Sachs | Neutral | Maintains | |
| 2022-08-04 | BMO Capital | Outperform | Maintains | |
| 2022-08-04 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-08-04 | UBS | Buy | Maintains | |
| 2022-08-04 | SVB Leerink | Outperform | Maintains | |
| 2022-06-14 | UBS | Buy | Initiate | |
| 2022-05-05 | RBC Capital | Outperform | Maintains | |
| 2022-05-05 | Piper Sandler | Overweight | Maintains | |
| 2022-04-06 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2022-03-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-03-02 | Piper Sandler | Overweight | Maintains | |
| 2022-03-02 | RBC Capital | Outperform | Maintains | |
| 2021-12-20 | SVB Leerink | Outperform | Maintains | |
| 2021-12-17 | Needham | Buy | Maintains | |
| 2021-10-08 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-10-05 | Citigroup | Buy | Initiate | |
| 2021-09-23 | Needham | Buy | Initiate | |
| 2021-08-16 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-06-22 | Barclays | Overweight | Maintains | |
| 2021-06-21 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-06-18 | SVB Leerink | Outperform | Maintains | |
| 2021-05-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-04-14 | Stifel | Buy | Maintains | |
| 2021-04-01 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-03-01 | UBS | Buy | Maintains | |
| 2021-02-24 | Piper Sandler | Overweight | Maintains | |
| 2021-02-24 | SVB Leerink | Outperform | Maintains | |
| 2021-02-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-01-29 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2020-11-03 | RBC Capital | Outperform | Maintains | |
| 2020-11-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-11-03 | SVB Leerink | Outperform | Maintains | |
| 2020-10-09 | Jefferies | Buy | Maintains | |
| 2020-10-09 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-10-09 | SVB Leerink | Outperform | Maintains | |
| 2020-09-14 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2020-08-13 | Wells Fargo | Overweight | Maintains | |
| 2020-07-23 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
| 2020-06-18 | B of A Securities | Buy | Maintains | |
| 2020-06-01 | SVB Leerink | Outperform | Maintains | |
| 2020-05-06 | SVB Leerink | Outperform | Maintains | |
| 2020-05-06 | BMO Capital | Outperform | Maintains | |
| 2020-05-06 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-04-30 | Wells Fargo | Overweight | Maintains | |
| 2020-04-30 | Oppenheimer | Outperform | Maintains | |
| 2020-04-06 | Jefferies | Buy | Initiate | |
| 2020-04-02 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-03-23 | B of A Securities | Buy | Maintains | |
| 2020-03-12 | Bernstein | Market Perform | Outperform | Upgrade |
| 2020-02-27 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-02-26 | JP Morgan | Overweight | Maintains | |
| 2020-02-26 | BMO Capital | Outperform | Maintains | |
| 2020-01-22 | Wells Fargo | Overweight | Maintains | |
| 2019-12-03 | Wells Fargo | Outperform | Maintains | |
| 2019-12-02 | Barclays | Overweight | Maintains | |
| 2019-08-21 | Piper Jaffray | Overweight | Neutral | Downgrade |
| 2019-06-11 | Barclays | Overweight | Initiate | |
| 2019-05-08 | Mizuho | Neutral | Maintains | |
| 2019-05-08 | BMO Capital | Outperform | Maintains | |
| 2019-03-20 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2019-03-08 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2019-02-27 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-12-12 | Oppenheimer | Outperform | Initiate | |
| 2018-11-08 | B. Riley FBR | Buy | Buy | Maintains |
| 2018-08-08 | Stifel Nicolaus | Buy | Buy | Maintains |
| 2018-08-08 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-07-11 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2018-07-10 | Citigroup | Buy | Buy | Maintains |
| 2018-06-26 | B. Riley FBR | Buy | Buy | Maintains |
| 2018-05-10 | B. Riley FBR | Buy | Buy | Maintains |
| 2018-05-09 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-03-19 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2018-02-28 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-02-20 | Bank of America | Buy | Buy | Maintains |
| 2018-01-02 | Leerink Swann | Outperform | Initiate | |
| 2017-11-08 | UBS | Buy | Maintains | |
| 2017-10-19 | FBR Capital | Buy | Initiate | |
| 2017-09-28 | Goldman Sachs | Neutral | Initiate | |
| 2017-09-25 | UBS | Buy | Maintains | |
| 2017-08-25 | H.C. Wainwright | Neutral | Initiate | |
| 2017-08-09 | Deutsche Bank | Buy | Maintains | |
| 2017-07-17 | Deutsche Bank | Buy | Maintains | |
| 2017-05-15 | RBC Capital | Top Pick | Initiate | |
| 2017-04-06 | Mizuho | Buy | Neutral | Downgrade |
| 2017-02-23 | Evercore ISI Group | Buy | Initiate | |
| 2016-12-16 | Cantor Fitzgerald | Overweight | Initiate | |
| 2016-08-25 | Janney Capital | Neutral | Initiate | |
| 2016-08-11 | Deutsche Bank | Buy | Maintains | |
| 2016-06-29 | BMO Capital | Outperform | Initiate | |
| 2016-06-06 | Goldman Sachs | Buy | Initiate | |
| 2016-06-02 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2016-04-25 | SunTrust Robinson Humphrey | Neutral | Buy | Upgrade |
| 2016-02-24 | Stifel Nicolaus | Buy | Maintains | |
| 2016-02-24 | Deutsche Bank | Buy | Maintains | |
| 2016-02-19 | Wells Fargo | Outperform | Initiate | |
| 2016-01-14 | Deutsche Bank | Buy | Maintains | |
| 2015-11-25 | Bernstein | Market Perform | Initiate | |
| 2015-11-10 | PiperJaffray | Overweight | Maintains | |
| 2015-11-10 | Mizuho | Outperform | Neutral | Downgrade |
| 2015-11-10 | Leerink Swann | Outperform | Maintains | |
| 2015-10-13 | Northland Securities | Outperform | Initiate | |
| 2015-10-09 | Mizuho | Neutral | Initiate | |
| 2015-10-08 | Mizuho | Buy | Initiate | |
| 2015-07-31 | Leerink Swann | Outperform | Maintains | |
| 2015-06-29 | UBS | Buy | Maintains | |
| 2015-05-08 | Leerink Swann | Outperform | Maintains | |
| 2015-04-13 | Deutsche Bank | Buy | Maintains | |
| 2015-02-20 | BMO Capital | Outperform | Initiate | |
| 2014-11-05 | Citigroup | Buy | Maintains | |
| 2014-11-05 | Stifel Nicolaus | Buy | Maintains | |
| 2014-08-19 | JP Morgan | Overweight | Initiate | |
| 2014-07-23 | Buckingham Research | Buy | Initiate | |
| 2014-07-16 | SunTrust Robinson Humphrey | Neutral | Initiate | |
| 2014-06-11 | Wells Fargo | Outperform | Initiate | |
| 2014-05-27 | Cantor Fitzgerald | Hold | Maintains | |
| 2014-05-09 | UBS | Buy | Maintains | |
| 2014-05-09 | Citigroup | Buy | Maintains | |
| 2014-05-09 | Leerink Swann | Outperform | Maintains | |
| 2014-04-17 | Canaccord Genuity | Buy | Initiate | |
| 2014-02-26 | Stifel Nicolaus | Buy | Maintains | |
| 2014-02-26 | Cantor Fitzgerald | Buy | Hold | Downgrade |
| 2013-12-16 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2013-12-04 | Cantor Fitzgerald | Buy | Maintains | |
| 2013-11-25 | Barclays | Overweight | Maintains | |
| 2013-11-13 | RF Lafferty | Buy | Maintains | |
| 2013-11-06 | Jefferies | Buy | Maintains | |
| 2013-09-17 | Goldman Sachs | Buy | Initiate | |
| 2013-05-31 | Stifel Nicolaus | Buy | Initiate | |
| 2013-03-28 | JMP Securities | Market Outperform | Initiate | |
| 2013-03-12 | Citigroup | Buy | Maintains | |
| 2013-03-11 | Cantor Fitzgerald | Buy | Initiate | |
| 2013-02-27 | UBS | Buy | Maintains | |
| 2013-02-27 | PiperJaffray | Overweight | Maintains | |
| 2013-02-25 | Bank of America | Buy | Initiate | |
| 2012-11-29 | UBS | Buy | Initiate | |
| 2012-11-27 | Citigroup | Buy | Initiate | |
| 2012-10-12 | Barclays | Overweight | Maintains | |
| 2012-09-27 | Brean Capital | Buy | Initiate | |
| 2012-09-18 | Guggenheim | Buy | Initiate | |
| 2012-08-08 | PiperJaffray | Overweight | Maintains | |
| 2012-05-23 | Credit Suisse | Outperform | Initiate | |
| 2012-05-23 | Oppenheimer | Outperform | Initiate | |
| 2012-04-27 | Jefferies | Buy | Maintains | |
| 2012-04-10 | Citigroup | Buy | Initiate | |
| 2012-03-01 | Jefferies | Buy | Maintains | |
| 2012-02-28 | Auriga | Buy | Maintains | |
| 2012-02-28 | PiperJaffray | Overweight | Maintains | |
| 2024-10-23 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-09-10 | Needham | Buy | Buy | Reiterate |
| 2024-11-21 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-11-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-21 | Needham | Buy | Buy | Reiterate |
| 2024-12-12 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-12-12 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-12-12 | Needham | Buy | Buy | Reiterate |
| 2025-02-27 | Barclays | Overweight | Overweight | Maintains |
| 2025-02-26 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2025-02-26 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-02-26 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-02-26 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-02-13 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2024-11-07 | TD Cowen | Buy | Buy | Maintains |
| 2024-11-07 | Needham | Buy | Buy | Reiterate |
| 2024-08-01 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-01 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-08-01 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-08-01 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-01 | Needham | Buy | Buy | Maintains |
| 2024-08-01 | Baird | Outperform | Outperform | Maintains |
| 2024-11-18 | Baird | Outperform | Outperform | Maintains |
| 2024-10-04 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-03-05 | Needham | Buy | Buy | Reiterate |
| 2024-08-19 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-03-10 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-03-07 | UBS | Neutral | Buy | Upgrade |
| 2025-03-06 | Truist Securities | Buy | Buy | Maintains |
| 2025-05-07 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-05-07 | Baird | Outperform | Outperform | Maintains |
| 2025-05-07 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-05-07 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-05-07 | Needham | Buy | Buy | Reiterate |
| 2025-02-26 | Needham | Buy | Buy | Maintains |
| 2024-12-10 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-08-29 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-04-10 | Needham | Buy | Buy | Reiterate |
| 2025-08-28 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-08-28 | Truist Securities | Buy | Buy | Maintains |
| 2025-08-28 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-08-28 | Needham | Buy | Buy | Reiterate |
| 2025-08-06 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-06-03 | Needham | Buy | Buy | Reiterate |
| 2025-06-11 | Needham | Buy | Buy | Reiterate |
| 2025-08-20 | Needham | Buy | Buy | Reiterate |
| 2025-07-22 | Morgan Stanley | Overweight | Overweight | Maintains |
